Latest posts
BioMoment
10 Sept, 01:26
https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-26-0198/787889/ERBB2-Activating-Mutations-Promote-Enhanced?redirectedFrom=fulltextBioMoment
10 Sept, 01:22
https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-26-0198/787889/ERBB2-Activating-Mutations-Promote-Enhanced?redirectedFrom=fulltextAmerican Association for Cancer ResearchERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic…Abstract. Purpose: Trastuzumab Deruxtecan (T-DXd) is a HER2-targeting ADC approved for HER2-positive and HER2-low metastatic breast cancer (MBC). Whether activating mutations in ERBB2 potentiate response to T-DXd in MBC is unknown. Experimental Design: Patients…BioMoment
9 Sept, 22:50
https://www.harbourbiomed.com/therapeutics/15.htmlBioMoment
9 Sept, 22:45
Porustobart vs Ipilimumab or Tremelimumab - ADCC Enhanced --> Efficient Treg Depletion - HCAb (Heavy Chain Only Antibody) --> Small Size for Tumor Penetration - Short PK --> Reduced Peripheral Toxicity - Higher Binding Affinity --> Durable PD EffectsBioMoment
9 Sept, 22:44
https://www.fiercebiotech.com/biotech/solstice-rises-225m-advance-second-gen-ctla-4-immunotherapyBioMoment
9 Sept, 22:39
https://www.fiercebiotech.com/biotech/solstice-rises-225m-advance-second-gen-ctla-4-immunotherapyFierce BiotechSolstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care. | Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy…BioMoment
9 Sept, 09:23
Tarlatamab + Durvalumab 1st Line Maintenance in ES-SCLC (Phase 3 DeLLphi-305) Highly Significant and Clinically Meaningful mOS BenefitsBioMoment
9 Sept, 09:22edited
https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancerBioMoment
9 Sept, 09:20
ES-SCLC; Tarlatamab + aPD-L1 1st Line Maintenance; Phase 1b (DeLLphi 303) - mOS 25.3m (From the Start of Maintenance) - Low Grade CRS & ICANS - Randomized phase 3 On-going (DeLLphi-305)AmgenIMDELLTRABioMoment
9 Sept, 00:51
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS7563American Society of HematologyTrial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with…AbstractBackground and Significance: Despite advances in multiple myeloma (MM) treatment, nearly all patients (pts) will relapse, highlighting the need forBioMoment
9 Sept, 00:51
GPRC5D CAR-T 'Arlocabtagene Autoleucel' Met Primary Endpoint of ORR & CR in Heavily Pretreated Patients w/ Exposed to Prior BCMA Targeted TherapyJournal of Clinical OncologyQUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple…TPS7563Background: There are limited treatment options for patients (pts) with RRMM who are triple-class exposed (TCEx: immunomodulatory drugs [IMiD], anti-CD38 antibodies [aCD38], and proteasome inhibitors [PI]) and quad-class exposed (QCEx: IMiD, aCD38…BioMoment
9 Sept, 00:49edited
https://www.businesswire.com/news/home/20260904976631/en/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Registrational-Phase-2-QUINTESSENTIAL-Trial-of-the-Potential-First-in-Class-GPRC5D-Directed-CAR-T-Cell-Therapy-Arlocabtagene-Autoleucel-...BioMoment
9 Sept, 00:47
🇨🇳 Simcere Zaiming Pharmaceutical submitted IPO application to HKSE: www1.hkexnews.hk/app/sehk/2026/… Zaiming Pharmaceutical is the wholly-owned subsidiary of Simcere Pharma, and focused on the research, development, and commercialization of innovative oncologyBusinesswireBristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First…BioMoment
9 Sept, 00:46
https://www.fiercepharma.com/pharma/fda-approves-astrazeneca-etcamah-opening-ctdna-guided-treatment-shift-breast-cancer?_gl=1w2yq4t_gcl_auOTc3NDg3MjEuMTc4ODgxOTM1OQ.._gaMzI4MzAxMDc1LjE3ODg4MTkzNTQ._ga_KG49J84SR4czE3ODg5MTQ3NzQkbzIkZzAkdDE3ODg5MTQ3NzQkajYwJGwwJGgwFierce PharmaFDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerIn a rare divergence from its own expert panel, the FDA hasBioMoment
8 Sept, 11:05
https://www.sciencedirect.com/science/article/abs/pii/S2213260026002535
BioMoment
8 Sept, 11:04
https://www.sciencedirect.com/science/article/abs/pii/S2213260026002535BioMoment
7 Sept, 10:29
RLT Landscape; Target & IsotopesBioMoment
7 Sept, 10:28
BioMoment
7 Sept, 08:44
Early Stage NSCLC Treatment LandscapeBioMoment
7 Sept, 08:44
Related Channels
Other channels in the same section of the catalogue.
